Improved insulin absorption for diabetes sufferers
New technology for improved absorption of certain proteins and macromolecules...
New technology for improved absorption of certain proteins and macromolecules within the gastrointestinal (GI) tract promises to greatly enhance insulin compliance among diabetes sufferers. Coremed's proprietary in vivo encapsulation (IVE) technology is a physiochemically triggered drug delivery system within the GI tract that is designed to overcome variables regarding physical barriers, digestive states, hydration status, membrane permeability, enzymatic degradation, and transit and peristaltic movement.Currently, the company is putting its Intesulin oral insulin through a series of proof-of-principle human trials. Trial II, which uses IVE will be compared with Trial I.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
